Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”), a leading supplier of high-value
products for gene expression analysis, today announced the launch of its 2012
global research grant program, open to researchers from academic and non-profit
institutions.

“We are proud to offer our continued support to microRNA researchers around the
world. With our grant program we give customers access to our world leading
products and services and new groundbreaking discoveries regarding the role of
microRNAs in developmental and pathological pathways”, said Senior Vice
President Sales & Marketing, Dr. Henrik Pfundheller.

The Exiqon Grant Program has been established with an internal seed funding of
$40,000 / €30,000 from which awards will be given to researchers to drive
projects enhancing the understanding of how microRNA expression and function
relates to normal cellular development, and/or disease-related cellular
pathways.

Recipients may use Exiqon Grant Program awards for the purchase of any Exiqon
microRNA product or service. Exiqon offers a complete product line for microRNA
investigation, including products for RNA isolation, microRNA profiling
(Microarray and qPCR), microRNA detection (qPCR, Northern blotting, in situ
hybridization), and microRNA Functional studies (Inhibitors, target site
blockers). Exiqon also offers microRNA profiling services for both microarray
and qPCR analysis, complete with full sample QC and customized data analysis
and reporting.

Researchers are invited to submit an abstract, describing their research area,
project goals, and proposed workflow (including products or services needed) no
later than Tuesday, 31st January 2012. Award conveyance through the Exiqon
Grant Program does not influence, and is not influenced by, any other existing
or potential sources of project funding.

Applications should be submitted electronically via the Grant Program webpage,
http://www.exiqon.com/grants. Grant recipients will be announced no later than
15th February 2012.

Additional information:

Additional information is available through Exiqon representatives located
across North America and Europe. Interested parties are also invited to contact
Exiqon at 1-888-647-2879 (U.S.) or +45 4566 0888 (EU).

See the full press release in the attached PDF or at
www.exiqon.com/investor/portal.

PressRelease_GrantProgram_120105.pdf